Hydrogen sulfide inhibits human platelet aggregation

Eur J Pharmacol. 2007 Mar 15;559(1):65-8. doi: 10.1016/j.ejphar.2006.12.011. Epub 2007 Jan 17.

Abstract

Gaseous mediators such as nitric oxide (NO) play a major regulatory role in the cardiovascular system homeostasis, including platelet aggregation. Here, we investigated whether hydrogen sulfide (H(2)S), a newly recognized endogenous mediator, can affects aggregation of human platelets, using sodium hydrogen sulfide (NaHS) as H(2)S-donor. NaHS inhibited platelet aggregation induced by ADP, collagen, epinephrine, arachidonic acid, thromboxane mimetic, U46619, and thrombin. H(2)S effect was not dependent by cAMP/cGMP generation, NO production or potassium-channels opening. NaHS concentrations (up to 10 mM) did not exert toxic effects on platelet viability. The possible protective role of endogenous H(2)S in cardiovascular system is discussed.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Blood Platelets / drug effects*
  • Colforsin / pharmacology
  • Cyclic AMP / physiology
  • Cyclic GMP / physiology
  • Dose-Response Relationship, Drug
  • Humans
  • Hydrogen Sulfide / pharmacology*
  • In Vitro Techniques
  • Nitric Oxide / biosynthesis
  • Platelet Aggregation Inhibitors*
  • Potassium Channels / drug effects
  • Potassium Channels / physiology

Substances

  • Platelet Aggregation Inhibitors
  • Potassium Channels
  • Colforsin
  • Nitric Oxide
  • Cyclic AMP
  • Cyclic GMP
  • Hydrogen Sulfide